NASDAQ:EIDXEidos Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eidos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $48.25 -0.57 (-1.17 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$47.65Now: $48.25▼$49.8750-Day Range$43.70MA: $48.06▼$52.0452-Week Range$28.00Now: $48.25▼$66.56Volume42,800 shsAverage Volume100,903 shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/ABeta-0.27 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingEidos Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.80, Eidos Therapeutics has a potential upside of 19.8% from its current price of $48.25.Amount of Analyst CoverageEidos Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesEidos Therapeutics has received 140 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEidos Therapeutics has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentEidos Therapeutics has received 52.38% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote “Outperform” if you believe EIDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEidos Therapeutics does not currently pay a dividend.Dividend GrowthEidos Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eidos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $250,000.00 in company stock.Percentage Held by Insiders70.10% of the stock of Eidos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.13% of the stock of Eidos Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eidos Therapeutics are expected to decrease in the coming year, from ($2.57) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eidos Therapeutics is -36.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eidos Therapeutics is -36.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEidos Therapeutics has a P/B Ratio of 10.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EIDX Previous Symbol CUSIPN/A CIKN/A Webwww.eidostx.com Phone415-887-1471Debt Debt-to-Equity Ratio0.12 Current Ratio16.97 Quick Ratio16.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.69 million Price / Sales69.67 Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book10.56Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-37,830,000.00 Net MarginsN/A Return on Equity-30.48% Return on Assets-26.79%Miscellaneous Employees28 Outstanding Shares38,540,000Market Cap$1.86 billion Next Earnings Date8/6/2020 (Estimated) OptionableNot Optionable NASDAQ:EIDX Rates by TradingView Receive EIDX News and Ratings via Email Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter. Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions How has Eidos Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EIDX shares have increased by 9.9% and is now trading at $48.25. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eidos Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eidos Therapeutics. When is Eidos Therapeutics' next earnings date? Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Eidos Therapeutics. How were Eidos Therapeutics' earnings last quarter? Eidos Therapeutics Inc (NASDAQ:EIDX) announced its quarterly earnings data on Friday, May, 8th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.07. View Eidos Therapeutics' earnings history. What price target have analysts set for EIDX? 10 brokers have issued 12-month price targets for Eidos Therapeutics' stock. Their forecasts range from $34.00 to $80.00. On average, they anticipate Eidos Therapeutics' share price to reach $57.80 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View analysts' price targets for Eidos Therapeutics. Has Eidos Therapeutics been receiving favorable news coverage? Media coverage about EIDX stock has trended very negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eidos Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Eidos Therapeutics. Who are some of Eidos Therapeutics' key competitors? Some companies that are related to Eidos Therapeutics include Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK) and Global Blood Therapeutics (GBT). View all competitors. What other stocks do shareholders of Eidos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Micron Technology (MU), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Pfizer (PFE), Roku (ROKU), Sangamo Therapeutics (SGMO) and Clovis Oncology (CLVS). Who are Eidos Therapeutics' key executives? Eidos Therapeutics' management team includes the following people: Dr. Neil Kumar, CEO & Director (Age 40)Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)Dr. Uma Sinha, Chief Scientific Officer (Age 62)Dr. Cameron Turtle, Chief Bus. Officer (Age 29)Dr. Hoyoung Huh, Consultant (Age 50) When did Eidos Therapeutics IPO? (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager. What is Eidos Therapeutics' stock symbol? Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX." How do I buy shares of Eidos Therapeutics? Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eidos Therapeutics' stock price today? One share of EIDX stock can currently be purchased for approximately $48.25. How big of a company is Eidos Therapeutics? Eidos Therapeutics has a market capitalization of $1.86 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe. What is Eidos Therapeutics' official website? The official website for Eidos Therapeutics is www.eidostx.com. How can I contact Eidos Therapeutics? Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2000, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
